Unlocking the therapeutic potential of Catharanthus roseus leaves via in-vitro, in-vivo, and in-silico study
Abstract
Catharanthus roseus (L.) (CR), is a perennial flowering herb, has traditionally been used by local populations in South Asia, Africa, China and Malaysia to treat diabetes, cancer and microbial infection. The principal objective of this study was to investigate the antidiabetic, antilipidemic and antiarthritic effects of methanol (MCR) and ethanol (ECR) extracts and dichloromethane fraction (DCR) of Catharanthus roseus leaves by in-vitro, in-vivo, and in-silico model. The in-vivo antihyperglycemic activity of C. roseus was explored in streptozotocin (STZ)-induced Type- 1 diabetic mice model. MCR, ECR and DCR exhibited a significant ability to lower fasting blood glucose levels and normalized the altered body weight when treatment was carried out for 20 days in a dose-dependent manner. Among the experimental samples, ECR at 200 mg/kg (4.95 ± 0.31 mmol/L) showed greater fasting blood glucose lowering activity than the standard drugs metformin (6.8 ± 0.34 mmol/L), and glibenclamide (5.20 ± 0.29 mmol/L). MCR at 200 mg/kg, likewise significantly (p < 0.001) reduced the blood glucose (5.70 ± 0.12 mmol/L) compared to the control at day 20. The lipid profile (LDL, HDL, TG, and TC) of diabetic mice was significantly reduced by ECR in a biochemical study compared to the control group. The in-vitro antidiabetic study revealed a dose-dependent hypoglycemic potential of the extracts and fraction; where ECR showed the highest α-amylase and α-glucosidase inhibitory effects with the IC50…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.